Compass Therapeutics (CMPX) EBT (2018 - 2026)
Compass Therapeutics (CMPX) posted EBT of -$53.2 million for Q1 2026, down 194.24% sequentially from -$18.1 million in Q4 2025, and down 219.91% YoY from $44.4 million in Q1 2025.
Compass Therapeutics (CMPX) EBT (2018 - 2026) Analysis & Trends
Compass Therapeutics has reported EBT for 9 years, with the latest figure at -$53.2 million in Q1 2026.
- Quarterly EBT fell 219.91% year-over-year to -$53.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$126.8 million (down 111.23% YoY) and the FY2025 annual result came in at -$152.0 million, down 31.06% from the prior year.
- EBT slipped to -$53.2 million in Q1 2026 per CMPX's latest filing, from -$18.1 million in the prior quarter.
- Over five years, EBT peaked at -$7.2 million in Q1 2022 and troughed at -$53.2 million in Q1 2026.
- A 5-year average of -$16.4 million and a median of -$13.1 million in 2024 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2026: EBT rose 16.79% in 2023, then tumbled 219.91% in 2026.
- Over 5 years, EBT stood at -$11.6 million in 2022, then dropped by 15.71% to -$13.4 million in 2023, then fell by 25.61% to -$16.8 million in 2024, then dropped by 7.32% to -$18.1 million in 2025, then plunged by 194.24% to -$53.2 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$53.2 million, -$18.1 million, and -$27.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | -38.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.08 Mn |
| Mar 31, 2026 | -53.21 Mn |
| Dec 31, 2025 | -18.08 Mn |
| Sep 30, 2025 | -27.37 Mn |
| Jun 30, 2025 | -28.11 Mn |
| Mar 31, 2025 | -16.63 Mn |
| Dec 31, 2024 | -16.85 Mn |
| Sep 30, 2024 | -13.46 Mn |
| Jun 30, 2024 | -13.08 Mn |
| Mar 31, 2024 | -10.79 Mn |
| Dec 31, 2023 | -13.42 Mn |
| Sep 30, 2023 | -9.96 Mn |
| Jun 30, 2023 | -11.28 Mn |
| Mar 31, 2023 | -7.84 Mn |
| Dec 31, 2022 | -11.59 Mn |
| Sep 30, 2022 | -11.98 Mn |
| Jun 30, 2022 | -8.49 Mn |
| Mar 31, 2022 | -7.16 Mn |
| Dec 31, 2021 | -12.99 Mn |
| Sep 30, 2021 | -5.98 Mn |